Companies
WuXi AppTec
a top-tier CRO whose Structure Biology Division integrates cryo-EM into its compound-library screening services for global clients.
- Country
- China
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | — | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Capacity | Over 4,000 kL total reactor volume for small molecule APIs and over 100,000 L for Solid Phase Peptide Synthesizers as of 2025 | wuxiapptec.com |
| Certification | ISO/IEC 27001, FDA GLP, OECD GLP, NMPA GLP, CNAS/A2LA ISO 17025, and other regulatory quality standards | moatmap.ai · wuxiapptec.com |
| Regulatory approval | Inspected and accepted by FDA, NMPA, OECD, PMDA, and MFDS inspectors | moatmap.ai · wuxiapptec.com |
| Production site | Main production and research sites include Shanghai, Wuxi, Suzhou, Changzhou, Taixing, and Jinshan in China, along with facilities in the United States, Germany, and Singapore | croscout.com · moatmap.ai |
| Headcount | 39,414 employees | globaldata.com |
| Revenue | RMB 45.46 billion for full-year 2025 | wuxiapptec.com |
Independent sources: croscout.com · globaldata.com · moatmap.ai
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Chemoenzymatic API synthesis (biocatalytic small-molecule manufacturing) | therapeutics-platforms | Low | → |
| Process validation and qualification (CRO) | therapeutics-platforms | Low | → |
| Proteomics (mass-spec CRO) | bioinformatics-omics | Medium | → |
| Structural biology (cryo-EM CRO) | bioinformatics-omics | Medium | → |
| Toxics screening (toxicomics, service) | bioinformatics-omics | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.